letrozole has been researched along with Endometrial Hyperplasia in 8 studies
Endometrial Hyperplasia: Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Letrozole and Megestrol acetate seem to have similar effects on the treatment of simple endometrial hyperplasia, the only difference being that Letrozole presents fewer side effects than Megestrol acetate in patients with this condition." | 9.24 | Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial. ( Mirmohammadkhanai, M; Moradan, S; Nikkhah, N, 2017) |
| "The aim of this survey was to compare the effect of letrozole with medroxyprogesterone acetate (MPA) in treatment of simple endometrial hyperplasia to preserve fertility in young women." | 9.17 | Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women. ( Dehghani, A; Dehghani-Tafti, M; Karimi Zarchi, M; Miratashi-Yazdi, A; Tabatabaie, A; Teimoori, S, 2013) |
| "To study letrozole as a primary therapeutic agent for endometrial hyperplasia with or without atypia in young women." | 9.13 | Letrozole as primary therapy for endometrial hyperplasia in young women. ( Chen, XN; Li, HZ; Qiao, J, 2008) |
| "To evaluate the efficacy and safety of gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine device (LNG-IUD) or aromatase inhibitor (letrozole) in women with endometrial carcinoma or atypical endometrial hyperplasia who wished to preserve fertility." | 8.12 | Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia. ( Cao, D; Chen, J; Cheng, N; Peng, P; Shen, K; Wang, J; Yang, J; Yu, M; Zhang, Y; Zhou, H, 2022) |
| "To evaluate the effects of letrozole (Ltz) in carcinogen+estrogen-induced endometrial hyperplasia." | 7.83 | Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice. ( Cândido, EB; Carneiro, MM; Carvalho-Macedo, AC; Lara, AC; Rocha, AL; Silva-Filho, AL; Vidigal, PV, 2016) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 7.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "Letrozole and Megestrol acetate seem to have similar effects on the treatment of simple endometrial hyperplasia, the only difference being that Letrozole presents fewer side effects than Megestrol acetate in patients with this condition." | 5.24 | Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial. ( Mirmohammadkhanai, M; Moradan, S; Nikkhah, N, 2017) |
| "The aim of this survey was to compare the effect of letrozole with medroxyprogesterone acetate (MPA) in treatment of simple endometrial hyperplasia to preserve fertility in young women." | 5.17 | Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women. ( Dehghani, A; Dehghani-Tafti, M; Karimi Zarchi, M; Miratashi-Yazdi, A; Tabatabaie, A; Teimoori, S, 2013) |
| "To study letrozole as a primary therapeutic agent for endometrial hyperplasia with or without atypia in young women." | 5.13 | Letrozole as primary therapy for endometrial hyperplasia in young women. ( Chen, XN; Li, HZ; Qiao, J, 2008) |
| "To evaluate the efficacy and safety of gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine device (LNG-IUD) or aromatase inhibitor (letrozole) in women with endometrial carcinoma or atypical endometrial hyperplasia who wished to preserve fertility." | 4.12 | Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia. ( Cao, D; Chen, J; Cheng, N; Peng, P; Shen, K; Wang, J; Yang, J; Yu, M; Zhang, Y; Zhou, H, 2022) |
| "To evaluate the effects of letrozole (Ltz) in carcinogen+estrogen-induced endometrial hyperplasia." | 3.83 | Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice. ( Cândido, EB; Carneiro, MM; Carvalho-Macedo, AC; Lara, AC; Rocha, AL; Silva-Filho, AL; Vidigal, PV, 2016) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 3.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "The aim of this study was to evaluate the efficacy and safety with gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine system or an aromatase inhibitor (letrozole) in young women with well-differentiated early endometrial carcinoma (EC) and complex atypical hyperplasia (CAH)." | 1.46 | Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women. ( Cao, D; Lang, J; Shen, K; Yang, J; Zhou, H, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Cao, D | 2 |
| Yang, J | 2 |
| Yu, M | 1 |
| Zhou, H | 2 |
| Cheng, N | 1 |
| Wang, J | 1 |
| Zhang, Y | 1 |
| Peng, P | 1 |
| Shen, K | 2 |
| Moradan, S | 1 |
| Nikkhah, N | 1 |
| Mirmohammadkhanai, M | 1 |
| Lang, J | 1 |
| Tabatabaie, A | 1 |
| Karimi Zarchi, M | 1 |
| Dehghani-Tafti, M | 1 |
| Miratashi-Yazdi, A | 1 |
| Teimoori, S | 1 |
| Dehghani, A | 1 |
| Zhao, PL | 1 |
| Zhang, QF | 1 |
| Yan, LY | 1 |
| Huang, S | 1 |
| Chen, Y | 1 |
| Qiao, J | 2 |
| Lara, AC | 1 |
| Cândido, EB | 1 |
| Vidigal, PV | 1 |
| Rocha, AL | 1 |
| Carvalho-Macedo, AC | 1 |
| Carneiro, MM | 1 |
| Silva-Filho, AL | 1 |
| Barker, LC | 1 |
| Brand, IR | 1 |
| Crawford, SM | 1 |
| Li, HZ | 1 |
| Chen, XN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for letrozole and Endometrial Hyperplasia
| Article | Year |
|---|---|
Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial.
Topics: Administration, Oral; Adult; Endometrial Hyperplasia; Female; Humans; Letrozole; Megestrol Acetate; | 2017 |
Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women.
Topics: Adult; Antineoplastic Agents, Hormonal; Biopsy; Curettage; Dizziness; Endometrial Hyperplasia; Estra | 2013 |
Letrozole as primary therapy for endometrial hyperplasia in young women.
Topics: Adult; Aromatase Inhibitors; Endometrial Hyperplasia; Endometrium; Female; Humans; Letrozole; Nitril | 2008 |
5 other studies available for letrozole and Endometrial Hyperplasia
| Article | Year |
|---|---|
Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia.
Topics: Aromatase Inhibitors; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Gonadotropin-Releasing | 2022 |
Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carcinoma, Endometrioid | 2017 |
Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases.
Topics: Androgens; Aromatase; Aromatase Inhibitors; Blotting, Western; Case-Control Studies; Cells, Cultured | 2014 |
Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinogenesis; Endo | 2016 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endo | 2009 |